GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptose Biosciences Inc (OTCPK:APTOF) » Definitions » Cyclically Adjusted FCF per Share

APTOF (Aptose Biosciences) Cyclically Adjusted FCF per Share : $-258.25 (As of Dec. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Aptose Biosciences Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Aptose Biosciences's adjusted free cash flow per share for the three months ended in Dec. 2024 was $-4.018. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-258.25 for the trailing ten years ended in Dec. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 10.10% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 16.60% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 26.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Aptose Biosciences was 33.50% per year. The lowest was 6.80% per year. And the median was 20.60% per year.

As of today (2025-05-12), Aptose Biosciences's current stock price is $1.65. Aptose Biosciences's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 was $-258.25. Aptose Biosciences's Cyclically Adjusted Price-to-FCF of today is .


Aptose Biosciences Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Aptose Biosciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptose Biosciences Cyclically Adjusted FCF per Share Chart

Aptose Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -600.86 -400.09 -351.26 -336.84 -258.25

Aptose Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -336.84 -316.98 -302.87 -295.58 -258.25

Competitive Comparison of Aptose Biosciences's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Aptose Biosciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptose Biosciences's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptose Biosciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Aptose Biosciences's Cyclically Adjusted Price-to-FCF falls into.


;
;

Aptose Biosciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aptose Biosciences's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-4.018/127.3637*127.3637
=-4.018

Current CPI (Dec. 2024) = 127.3637.

Aptose Biosciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201503 -70.731 99.789 -90.276
201506 -136.308 100.500 -172.743
201509 -75.038 100.421 -95.170
201512 -119.074 99.947 -151.737
201603 -129.111 101.054 -162.726
201606 -133.074 102.002 -166.162
201609 -85.931 101.765 -107.547
201612 -94.258 101.449 -118.336
201703 -68.026 102.634 -84.417
201706 -56.170 103.029 -69.437
201709 -39.453 103.345 -48.623
201712 -48.119 103.345 -59.303
201803 -62.738 105.004 -76.098
201806 -123.773 105.557 -149.343
201809 -58.390 105.636 -70.400
201812 -68.422 105.399 -82.681
201903 -55.034 106.979 -65.521
201906 -51.408 107.690 -60.799
201909 -42.488 107.611 -50.287
201912 -48.008 107.769 -56.737
202003 -48.089 107.927 -56.749
202006 -42.609 108.401 -50.062
202009 -43.298 108.164 -50.983
202012 -52.409 108.559 -61.487
202103 -52.490 110.298 -60.612
202106 -44.571 111.720 -50.812
202109 -41.616 112.905 -46.945
202112 -80.693 113.774 -90.331
202203 -47.049 117.646 -50.936
202206 -34.493 120.806 -36.365
202209 -34.044 120.648 -35.939
202212 -42.200 120.964 -44.433
202303 -54.864 122.702 -56.948
202306 -65.058 124.203 -66.713
202309 -48.778 125.230 -49.609
202312 -35.340 125.072 -35.987
202403 -26.856 126.258 -27.091
202406 -10.355 127.522 -10.342
202409 -16.763 127.285 -16.773
202412 -4.018 127.364 -4.018

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Aptose Biosciences  (OTCPK:APTOF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Aptose Biosciences Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Aptose Biosciences's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptose Biosciences Business Description

Traded in Other Exchanges
Address
66 Wellington Street West, Suite 5300, TD Bank Tower Box 48, Toronto, ON, CAN, M5K 1E6
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
Executives
William G. Rice director, officer: Chair, President & CEO C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Bernd R. Seizinger director 535 BOYLSTON STREET, BOSTON MA 02116
Fletcher Payne officer: SR VP & Chief Fin. Officer 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Philippe Ledru officer: Chief Commercial Officer C/O APTOSE BIOSCIENCES INC., 2511 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Denis R Burger director CYTODYN INC., 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Erich Platzer director
Rafael Bejar officer: Chief Medical Officer C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Wilson Donald R. Jr. 10 percent owner 540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Drw Holdings, Llc 10 percent owner 540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Drw Commodities, Llc 10 percent owner 540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Warren Whitehead director C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Gregory K. Chow officer: Senior VP & CFO C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Jotin Marango officer: Senior VP, Chief Bus. Officer C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Mark D. Vincent director C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3